AUXL Related Analyst Ratings
-
Morgan Stanley Upgrades Auxilium Pharmaceuticals (AUXL) to Equalweight
-
Jefferies Lowers Numbers on Auxilium Pharmaceuticals (AUXL) Post Q1
-
Stifel Nicolaus Upgrades Auxilium Pharmaceuticals (AUXL) to Buy
-
Auxilium's (AUXL) Testosterone Gel Growth Encouraging, Say Analysts
-
WallachBeth Capital Starts Auxilium Pharmaceuticals (AUXL) at Buy
-
UBS Maintains a 'Buy' in Auxilium Pharmaceuticals (AUXL); Positive Physician Survey Results
-
Morgan Stanley Downgrades Auxilium Pharmaceuticals (AUXL) to Underweight
-
Aegis Capital Starts Auxilium Pharmaceuticals (AUXL) at Buy
-
UPDATE: MKM Partners Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral; Valuation Call
-
Canaccord Genuity Raises Price Target on Auxilium Pharmaceuticals (AUXL); Testim Tests Well
-
Stifel Nicolaus Downgrades Auxilium Pharmaceuticals (AUXL) to Hold
-
Leerink Swann Downgrades Auxilium Pharmaceuticals (AUXL) to Market Perform on Valuation; Outlook Mixed
-
Oppenheimer Maintains a 'Perform' on Auxilium Pharmaceuticals (AUXL); Reaching Out To Urologists
-
UPDATE: Leerink Swann Raises Auxilium Pharma (AUXL) to Outperform; Surprise From Phase III Trials
-
Canaccord Genuity Maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Meeting With CEO
-
MKM Partners Upgrades Auxilium Pharmaceuticals (AUXL) to Buy
-
Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
-
Canaccord Genuity Maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Q1 Review; All Eyes on P3 Xiaflex Data
-
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
-
Canaccord Genuity Starts Auxilium Pharmaceuticals (AUXL) at Buy
-
Deutsche Bank Raises Price Target on Auxilium Pharmaceuticals (AUXL) to $22 After Q4
-
Leerink Swann Boosts Price Target On Auxilium (AUXL), Sees Equal Risk/Reward
-
RBC Capital Upgrades Auxilium Pharmaceuticals (AUXL) to Outperform
-
MKM Says Addition of Adams Could Spur Takeover Chatter in Auxilium (AUXL)
-
Jefferies Cuts Price Targets on Auxilium Pharmaceuticals (AUXL) As Xiaflex Sales Remain Weak
-
UBS Maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Conference Call Takeaways
-
Collins Stewart Upgrades Auxilium Pharmaceuticals (AUXL) to Buy; Positive Risk/Reward for Peyronie's
-
ThinkEquity Starts Auxilium Pharmaceuticals (AUXL) at Sell
-
Citi Upgrades Auxilium Pharmaceuticals (AUXL) to Buy
-
MKM Partners Starts Auxilium Pharmaceuticals (AUXL) at Neutral
-
Brean Murray Carret Cuts Price Target on Auxilium Pharmaceuticals (AUXL), Still Very Bearish
-
Jefferies Trims Numbers On Auxilium Pharmaceuticals (AUXL) After Weak 2Q Xiaflex Sales
-
UPDATE - UBS Initiates Coverage on Auxilium Pharmaceuticals (AUXL) with a Buy; Diamond in the Rough
-
UBS Starts Auxilium Pharmaceuticals (AUXL) at Buy
-
Jefferies Raises Price Target on Auxilium Pharmaceuticals (AUXL), Partnership With Asahi Kasei Pharma To Release Xiaflex in Japan
-
Morgan Stanley Downgrades Auxilium Pharmaceuticals (AUXL) to Equalweight
-
Jefferies Continues to Feel Good About Auxilium Pharmaceuticals (AUXL), Maintains Buy Rating
-
Collins Stewart Downgrades Auxilium Pharma (AUXL) to Neutral
-
Citi Maintains a 'Hold' Rating on Auxilium Pharmaceuticals (AUXL); Prefers BMRN
-
Citi 2Q10 SMID Biotech Earnings Preview: Adjusting AUXL & DNDN Models Ahead of Earnings; Top-Pick is BioMarin (BMRN)
-
Oppenheimer Downgrades Auxilium Pharmaceuticals (AUXL) to Perform
-
Global Hunter Securities Suggest Investors Acquire a Basket of Biotech Stocks
-
Global Hunter Securities Initiates Coverage on Several Biotech Stocks; Sees Glass "Half Full"
-
Noble Financial Initiates Coverage on Auxilium Pharmaceuticals (AUXL) with a Buy
-
Hapoalim Securities Downgrades Auxilium Pharmaceuticals (AUXL) to Hold
-
Caris & Company Upgrades Auxilium Pharma (AUXL) to Average
-
Leerink Swann Downgrades Auxilium Pharmaceuticals (AUXL) to Market Perform; Reimbursement Headwinds
-
Jefferies & Co Initiates Coverage on Biotechnology and Drugs Stocks
-
Bank of America Resumes Coverage on Auxilium Pharmaceuticals (AUXL) with a Buy
-
Deutsche Bank Maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Positive on Pipeline Product Xiaflex
Back to AUXL Stock Lookup
